MIRA Says Oral Ketamine Analog, Ketamir-2, Showed Significantly Greater Efficacy Than FDA-Approved Treatments Gabapentin (Neurontin) And Pregabalin (Lyrica) In Recent Preclinical Models Of Neuropathic Pain - Filing
Portfolio Pulse from Benzinga Newsdesk
MIRA Pharmaceuticals reports that its oral ketamine analog, Ketamir-2, has shown greater efficacy than FDA-approved treatments Gabapentin and Pregabalin in preclinical models of neuropathic pain. The company is conducting further studies and plans to submit an IND application by the end of 2024, with Phase I trials in Q1 2025.
October 21, 2024 | 11:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MIRA Pharmaceuticals' Ketamir-2 shows promising results in preclinical models, outperforming Gabapentin and Pregabalin. The company is on track for an IND application by 2024 and Phase I trials in 2025.
The promising preclinical results of Ketamir-2 suggest potential future success in clinical trials, which could positively impact MIRA's stock. The timeline for IND application and trials indicates progress in their development pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100